Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML

Tara L Lin, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Daniel H. Ryan, Robert Ryan, Michael Chiarella, Arthur C. Louie, Geoffrey L. Uy, MD

Blood (2018) 132 (Supplement 1): 2706.

https://doi.org/10.1182/blood-2018-99-112557

Published: 2018

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Daniel H. Ryan, Geoffrey L. Uy, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert Ryan, Michael Chiarella, Arthur C. Louie, Jeffrey E. Lancet, MD

Blood (2018) 132 (Supplement 1): 1425.

https://doi.org/10.1182/blood-2018-99-111514

Published: 2018

Journal Articles

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Blood (2018) 132 (Supplement 1): 563.

https://doi.org/10.1182/blood-2018-99-110439

Published: 2018

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies

Blood (2017) 130 (Supplement 1): 2657.

https://doi.org/10.1182/blood.V130.Suppl_1.2657.2657

Published: 2017

Journal Articles

Multivariate Efficacy Analysis of a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Geoffrey L. Uy, MD, Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Tara L. Lin, MD, Ellen K Ritchie, MD, Robert K. Stuart, MD, Stephen A Strickland, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, Jonathan E. Kolitz, MD, Gary J. Schiller, Matthew J. Wieduwilt, Lynn Shemanski, Michael Chiarella, Arthur C Louie, Bruno C Medeiros, MD

Blood (2017) 130 (Supplement 1): 2647.

https://doi.org/10.1182/blood.V130.Suppl_1.2647.2647

Published: 2017

Journal Articles

Prognosis and Application of Day 14 Bone Marrow Results in Acute Myeloid Leukemia Induction

James England, MD, Lalit Saini, MD, Donna Hogge, Artur J Szkotak, MD PhD, Joseph M. Brandwein, MD FRCPC, Monika Hudoba, MD, Nadejda Medvedev, MD, Tyler Smith, MD, Roland Kristine, MD, David Sanford, MD

Blood (2017) 130 (Supplement 1): 3917.

https://doi.org/10.1182/blood.V130.Suppl_1.3917.3917

Published: 2017

Journal Articles

Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis

Wasithep Limvorapitak, MD, Michael J Barnett, BM, Donna Hogge, Donna L Forrest, MD, Thomas J Nevill, MD, Sujaatha Narayanan, MBBS, Maryse Power, MB, Stephen H Nantel, MD, Raewyn Broady, MBChB, FRACP, Kevin W Song, MD, Cynthia L Toze, MD, Yasser Abou Mourad, MD, Heather Sutherland, MD, Alina S Gerrie, MD, Jennifer White, MD, David Sanford, MD

Blood (2017) 130 (Supplement 1): 4544.

https://doi.org/10.1182/blood.V130.Suppl_1.4544.4544

Published: 2017

Journal Articles

Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics

Daniel Sawler, MD BSc, David Sanford, MD, Joseph M. Brandwein, MD FRCPC, Irwindeep Sandhu, MDFRCPC, Donna Hogge, Lalit Saini, MD

Blood (2017) 130 (Supplement 1): 464.

https://doi.org/10.1182/blood.V130.Suppl_1.464.464

Published: 2017

Journal Articles

Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Bruno C Medeiros, MD, Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Tara L. Lin, MD, Ellen K Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD MSCI, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, Jonathan E. Kolitz, MD, Gary J. Schiller, Matthew J. Wieduwilt, Robert J. Ryan, Michael Chiarella, Arthur C Louie, Geoffrey L. Uy, MD

Blood (2017) 130 (Supplement 1): 1366.

https://doi.org/10.1182/blood.V130.Suppl_1.1366.1366

Published: 2017

Journal Articles

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

Blood (2016) 128 (22): 906.

https://doi.org/10.1182/blood.V128.22.906.906

Published: 2016

Journal Articles

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Blood (2016) 128 (22): 902.

https://doi.org/10.1182/blood.V128.22.902.902

Published: 2016

Journal Articles

Distinct but phenotypically heterogeneous human cell populations produce rapid recovery of platelets and neutrophils after transplantation

Alice M. S. Cheung, Donna Leung, Shabnam Rostamirad, Kiran Dhillon, Paul H. Miller, Radina Droumeva, Ryan R. Brinkman, Donna Hogge, Denis Claude Roy, Connie J. Eaves

Blood (2012) 119 (15): 3431–3439.

https://doi.org/10.1182/blood-2011-12-398024

Published: 2012

Includes: Supplemental data

Journal Articles

Photodepletion differentially affects CD4 + Tregs versus CD4 + effector T cells from patients with chronic graft-versus-host disease

Jean-Philippe Bastien, Gorazd Krosl, Cynthia Therien, Marissa Rashkovan, Christian Scotto, Sandra Cohen, David S. Allan, Donna Hogge, R. Maarten Egeler, Claude Perreault, Denis Claude Roy

Blood (2010) 116 (23): 4859–4869.

https://doi.org/10.1182/blood-2010-03-273193

Published: 2010

Includes: Supplemental data

Journal Articles

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Mats Brune, MD, Sylvie Castaigne, MD, John Catalano, MD, Kurt Gehlsen, PhD, Wolf-Karsten Hofmann, MD, Anthony Ho, MD, Donna Hogge, MD, Bo Nilsson, MD, Reuven Or, MD, Jacob Rowe, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Edward Stadtmauer, MD, Jeff Szer, MD, Elisabeth Wallhult, RN, Kristoffer Hellstrand, MD

Blood (2004) 104 (11): 261.

https://doi.org/10.1182/blood.V104.11.261.261

Published: 2004

Journal Articles

Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog

Blood (2003) 102 (10): 3743–3752.

https://doi.org/10.1182/blood-2003-01-0108

Published: 2003

Journal Articles

Diphtheria Toxin Fused to Granulocyte-Macrophage Colony-Stimulating Factor Is Toxic to Blasts From Patients With Juvenile Myelomonocytic Leukemia and Chronic Myelomonocytic Leukemia

Arthur E. Frankel, Michael Lilly, Robert Kreitman, Donna Hogge, Miloslav Beran, Melvin H. Freedman, Peter D. Emanuel, Chris McLain, Philip Hall, Edward Tagge, Marc Berger, Connie Eaves

Blood (1998) 92 (11): 4279–4286.

https://doi.org/10.1182/blood.V92.11.4279

Published: 1998

NARROW

The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies

Multivariate Efficacy Analysis of a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Prognosis and Application of Day 14 Bone Marrow Results in Acute Myeloid Leukemia Induction

Outcomes of Intermediate Risk Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared to Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-Score Adjusted Analysis

Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics

Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Distinct but phenotypically heterogeneous human cell populations produce rapid recovery of platelets and neutrophils after transplantation

Photodepletion differentially affects CD4 + Tregs versus CD4 + effector T cells from patients with chronic graft-versus-host disease

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog

Diphtheria Toxin Fused to Granulocyte-Macrophage Colony-Stimulating Factor Is Toxic to Blasts From Patients With Juvenile Myelomonocytic Leukemia and Chronic Myelomonocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only